Publications 2024

Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
World J Urol, 42 (1), 95
DOI 10.1007/s00345-024-04787-8, PubMed 38386171

Publications 2022

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
Pathol Res Pract, 241, 154243
DOI 10.1016/j.prp.2022.154243, PubMed 36481650

Publications 2021

Guerriero I, Ramberg H, Sagini K, Ramirez-Garrastacho M, Taskén KA, Llorente A (2021)
Implication of β2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells
PLoS One, 16 (6), e0253828
DOI 10.1371/journal.pone.0253828, PubMed 34191854

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362

Publications 2020

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Publications 2019

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β₂-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Publications 2016

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
DOI 10.18632/oncotarget.6479, PubMed 26646591

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
DOI 10.1002/ijc.30220, PubMed 27273830

Publications 2015

Braadland PR, Ramberg H, Grytli HH, Taskén KA (2015)
β-Adrenergic Receptor Signaling in Prostate Cancer
Front Oncol, 4, 375
DOI 10.3389/fonc.2014.00375, PubMed 25629002

Publications 2013

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA (2013)
TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells
Cancer Cell Int, 13 (1), 4
DOI 10.1186/1475-2867-13-4, PubMed 23368843

Publications 2012

Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A (2012)
The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy
Br J Nutr, 108 (12), 2138-47
DOI 10.1017/S0007114512000384, PubMed 22397815

Publications 2011

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ (2011)
Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial
Nutr Cancer, 63 (6), 889-98
DOI 10.1080/01635581.2011.582221, PubMed 21714686

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA (2011)
Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
Mol Cancer, 10, 50
DOI 10.1186/1476-4598-10-50, PubMed 21548940

Publications 2008

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA (2008)
Hormonal regulation of beta2-adrenergic receptor level in prostate cancer
Prostate, 68 (10), 1133-42
DOI 10.1002/pros.20778, PubMed 18454446

Publications 2006

Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA (2006)
Androgen dependent regulation of protein kinase A subunits in prostate cancer cells
Cell Signal, 19 (2), 401-9
DOI 10.1016/j.cellsig.2006.07.011, PubMed 16949795

Publications 2004

Ramberg H, Eide T, Krobert KA, Tindall DJ, Levy FO, Taskén KA (2004)
Beta2-adrenergic receptor regulation in prostate cancer upon androgen deprivation
In European urology supplements, Elsevier Science, Oxford, 3(2004)2, Abstrakt 581
BIBSYS 052053962

Publications 2000

Olson BJ, Skavdahl M, Ramberg H, Osterman JC, Markwell J (2000)
Formate dehydrogenase in Arabidopsis thaliana: characterization and possible targeting to the chloroplast
Plant Sci, 159 (2), 205-212
DOI 10.1016/s0168-9452(00)00337-x, PubMed 11074273